Efficacy was demonstrated in ALS, where autologous Tregs expanded in vitro and were administered intravenously with concomitant IL-2, slowing the rate of progression in both the early and late stages of the disease [101]. The gene discussed is IL2; the disease is amyotrophic lateral sclerosis.